Ruggedness of Visible-Residue Limits for Cleaning (Part II) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ruggedness of Visible-Residue Limits for Cleaning (Part II)
The author challenges current detection methodologies.


Pharmaceutical Technology
Volume 35, Issue 3, pp. 122-128

Method


Table III: Residue concentrations.
A series of four previously studied compounds with established VRLs, listed in Table II, were diluted with methanol to sequentially lower concentrations. The coupons were prepared using 100 µL of each solution resulting in four residue levels. The target concentrations were the four lowest concentrations shown in Table I: 20 µg, 10 µg, 5 µg, and 1 µg. One residue level was spotted per coupon. The spotted samples dried as elliptical residues. The resulting residue concentrations were calculated using the two elliptical radii in Table III based on the amount of residue spotted and the area of the resulting residue.


Table IV: Random coupon identification grid.
The coupons were arranged in a random order as shown in Table IV and Figure 1. Sixteen sample coupons and four solventblank coupons were prepared. In addition, five blank coupons brought the total matrix to 25 coupons in a five-by-five array.


Figure 1: Random coupon presentation.
The viewing parameters had been established previously: viewing distance was 18 in., viewing angle was 30°, and ambient light intensity was > 200 lux (1). Eight observers participated in the study. The observers viewed the coupon array separately from one another to avoid influencing their individual choices. The results for the random determinations are presented in Table V.


Table V: Observer results.
After the observations were completed for the random coupon presentation, the residues were ordered sequentially, two observers were brought back to view the coupons, and their observations were recorded (see Table V). The sequential presentation was a confirmation for the previously established VRLs because the residue preparations were, in some cases, much lower than the reference VRL and because every residue preparation is slightly different based on the amount of compound weighed and the area of the resulting residue.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
100%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
0%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Key Ways for Ensuring Global Regulatory Compliance
Source: Pharmaceutical Technology,
Click here